Previous 10 | Next 10 |
Summary Acumen has ACU193, an anti-amyloid oligomer antibody and its only drug candidate, in a Phase 1 trial. The Eisai news on lecanemab led to Acumen’s share price more than doubling. ACU193's mechanism of action builds on scientific publications identifying amyloid o...
The shares of microcap biotech Acumen Pharmaceuticals, Inc. ( NASDAQ: ABOS ) more than doubled in value on Wednesday after its rivals Biogen ( BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESALY ) announced promising late-stage data for experimental Alzheimer's therapy,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news from Biog...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it’s not due to any news from the company. Instead, investors have Biogen (NAS...
Why Are Alzheimer’s Stocks Up Today? This article discusses a handful of penny stocks with exposure to potential Alzheimer’s disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB )...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we check out what’s going on on Wednesday morning. Moving shares this morning are clinical trial...
Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q2 2022 Earnings Call Aug 15, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Tran...
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Conference Call August 15, 2022 04:30 PM ET Company Participants John Woolford - Investor Relations, Westwicke Daniel O'Connell - President & Chief Executive Officer Eric Siemers - Chief Medical Officer ...
Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q2 GAAP EPS of -$0.25 in-line. Cash Balance. As of June 30, 2022, cash, cash equivalents and marketable securities totaled $209.9 million For further details see: Acumen Pharmaceuticals GAAP EPS of -$0.25 in-...
Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD) Key methods and assay...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...